Abstracts

2020


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


2018


2017

Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


2016


• de Boer SM, Powell ME, Mileshkin LR, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Comolbo A, Fyles AW, Baron M-H, Kitchener HC, Nijman H, Kruittwagen RFPM, Jurgenlienm-Shultz IM, Nout RA, Smit VTHBM, Putter H, Creutzberg CL. Final results of the international randomized PORTEC-3 trial of adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-
Abstracts
Published on Canadian Cancer Trials Group (https://www.ctg.queensu.ca)


- Strasser-Weippl K, Sudan G, Ramjeesingh R, Shepherd LE, O'Shaughnessy J, Chen BE, Parulekar WR, Liedke PER, Goss PE. Outcomes of invasive ductal (ID) or invasive lobular (IL) early stage breast cancer in women treated with anastrozole or exemestane


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

2015


Parimi S, Karachiwala H, Lin Y, Monzon JG, Tam VC, Chen EX, Dancey J, Tang PA. Critical assessment of phase 0 (Ph0) and window of opportunity (WOO) trials: Definitions and reporting. J Clin Oncol 33[suppl; abstr e17710].


Pennimg M. Full report of the TROG 03.01, NCIC CTG ES2 multinational phase III study in advanced esophageal cancer comparing palliation of dysphagia and quality of life in patients treated with radiotherapy or chemoradiotherapy. J Clin Oncol 33[(suppl 3; abstr 6)]. 2015.


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


metformin (Met) to placebo (Pl). J Clin Oncol 32:5s[ suppl; abstr 542]. 2014.


2013


---


- Liedke PER, Chavarri-Guerra Y, Shepherd LE, Tu D, Pritchard KI, Goss PE. Vasomotor (VM) and musculoskeletal (MSK) symptoms and association with outcomes on extended adjuvant letrozole therapy: Analyses from NCIC CTG MA.17. J Clin Oncol 30[suppl, abstr 524], 2012.


- Pitz MW, MacNeil MV, Macdonald DR, Kakumanu AS, Thiessen B, Tsao MS, Kamel-


- Steele R, Quirke P, Grieve R, Monson J, Couture J, de Metz C, Pugh C, Nichols L, Thompson LC, Sebag-Montefiore D, on behalf of all investigators MCTUL. Long Term Outcome After Anastomotic Leak and the Impact of Short Course Pre-Operative Radiotherapy - Data from the MRC CRO7 NCIC CO16 trial. 6th European Multidisciplinary Colorectal Cancer Congress, 2012.


- Waldron JN, Parulekar W, O’Sullivan B, Chen BE, Montenegro A, Nabid A, Winquist E,
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


2011


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

suppl 2, abstr MO19.03, S641, 2011.


• Li X, Chen J, Wu Y, Tu D. Variable selections in the Cox proportional hazards model based on extended bayesian information criteria. 32nd Annual Conference of the International Society for Clinical Biostatistics, 2011.


• Meyer RM, Gospodarowicz M, Connors JM, Pearcey RG, Wells WA, Winter JN, Hornin SJ, Dar AR, Shustik C, Stewart DA, Crump M, Djurfeldt MS, Chen BE, Shepherd LE. Final Analysis of a Randomized Comparison of ABVD Chemotherapy with a Strategy


2010


- Alberts SR, Sargent DJ, Smyrk TC, Shields AF, Chan E, Goldberg RM, Gill S, Kahnemberg MS, Thibodeau SN, Nair S. Adjuvant mFOLFOX6 with or without cetuximab in KRAS wild-type patients with resected stage III colon cancer: Results from NCCTG Intergroup Phase III Trial N0147. J Clin Oncol 28[18s, abstr CRA3507], 2010.


• Chia SK, Ung K, Bramwell VH, Tu D, Perou CM, Ellis MJ, Bernard PS, Vickery T, Shepherd LE, Nielsen TO. Prognostic and predictive impact of biologic classification by qRT-PCR with a 50-gene subtype predictor for adjuvant tamoxifen in premenopausal breast cancer: Results from the NCIC CTG MA.12 randomized trial. J Clin Oncol 28[15s, abstr 508], 2010.


• Eisenhauer E. In search of intermediate endpoints. EORTC-NCI-AACR Symposium [abstr 29], 2010.


Radich JP, Kopecky KJ, Kamel-Reid S, Stock W, Paietta E, Wadleigh M, Larson RA, Emanuel PD, Tallman MS, Lipton J, Couban S, Deininger MW, Appelbaum FR, Druker BJ. A Randomized Phase II Trial of Dasatinib 100 Mg Vs Imatinib 400 Mg In Newly


Abstracts
Published on Canadian Cancer Trials Group (https://www.ctg.queensu.ca)

2010.


2009


- Craddock KJ, Buys TPH, Zhu CQ, Strumpf D, Pintillie M, Ding K, Seymour L, Jurisica I, Shepherd FA, Lam WL, Tsao M-S. High resolution genomic analysis of NSCLC reveals regions of DNA copy number gain that may be predictive of benefit from adjuvant chemotherapy. J Thoracic Oncol 4[9 suppl 1, abstr PD12.2.6], S580. 2009.


with lapatinib or trastuzumab as first-line therapy for women with HER2/neu positive metastatic breast cancer (NCIC CTG MA.31/EGF108919). ASCO Breast Cancer Symposium, 2009.


- Kouroukis CT, Hafid T, Wong J, Kovacs MJ, Barr R, Findlay B, Shepherd L, Djurfeldt M, Ding K, Zhu L, Shustik C, Meyer R. Comorbidity, age and performance status are important predictors of outcome in older multiple myeloma patients treated with melphalan and corticosteroids; subgroup analysis from the National Cancer Institute of


Palmer M, Broxterman J, Shepherd L, Parulekar W. Tracking patients on an intergroup oncology study. It’s a snap! Clinical Trials 6, 536, 2009.


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


2008

- Bradbury PA, Tu D, Seymour L, Ng R, Zhu L, Isogai PK, Mittmann N, Evans WK, Shepherd FA, Leighl NB, on behalf of the NCIC CTG Working Group on Economic Analysis. Impact of clinical and molecular predictors of benefit from erlotinib in advanced
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


patients with organ confined node negative bladder cancer treated with radical cystectomy. Society of Urologic Oncology, 2008.


- Pollak MN, Chapman JW, Pritchard KI, Krook JE, Dhaliwal HS, Vandenberg TA, Norris BD, Whelan TJ, Wilson CF, Shepherd LE. NCIC-CTG MA14 trial: Tamoxifen (tam) vs. tam + octreotide (oct) for adjuvant treatment of stage I or II postmenopausal breast

Schell AJ, Young I, Hansen C, Chi KN, Taylor S. BRAF mutation status and growth factor receptor expression do not predict baseline factors or outcome in hormone refractory prostate carcinoma. United States and Canadian Academy of Pathology, 2008.


Vergote I, Tropé CG, Amant F, Kristensen GB, Sardi JE, Ehlen T, Johnson N, Verheijen...
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


• Zhu L, Tan X, Tu D. Testing the homogeneity of two survival functions against a mixture alternative based on censored data. Statistical Society of Canada, 2008.

2007


• Au H-J, Brundage M, Ringash J, Bezjak A, Palmer M, Richardson H, Lee CW, Maunsell


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


trial in prostate cancer of radiotherapy timing and hormone therapy duration after radical prostatectomy (MRC PR10, NCIC PR13, ISRCTN40814031). NCRI United Kingdom, 2007.


• Tu D. Identification of patients who will benefit from a treatment based on their genetic profiles: Some examples and statistical issues. Workshop on Statistical Analysis of High-Throughput Genetic Data, 2007.


2006


• Chen CI, Kouroukis T, White D, Voralia M, Stadtmauer E, Wright J, Powers J, Eisenhauer E. Bortezomib is active in Waldenström's Macroglobulinemia (WM) - Results
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

of a NCIC Clinical Trials Group phase II study in previously untreated or treated WM. 

- Chen E, Zhang W, Laurie S, Arnold A, Gauthier I, Goss G, Ellis P, Shepherd F, 
  Matthews S, Seymour L. Effects of AZD2171 on pharmacokinetics of carboplatin and 
  paclitaxel in patients with advanced non-small cell lung cancer: a study of the NCIC 

- Chen E, Jonker D, Gauthier I, MacLean M, Wells J, Matthews S, Robertson J, Seymour 
  L. Phase I study of daily oral AZD2171, an inhibitor of the vascular endothelial growth 
  factor receptors, in combination with oxaliplatin and infusional 5FU (mFOLFOX6) in 
  patients with advanced colorectal cancer: a study of the NCIC Clinical Trials Group. Eur 

- Chi KN, Ellard S, Hotte SJ, Czaykowski P, Moore M, Ruether JD, Hansen C, Seymour L. 
  Phase II study of BAY 43-9006 (sorafenib) in patients with chemo-naive hormone 

- DeAngelo DJ, Silverman LB, Couban S, Dahlberg S, Amrein P, Seftel MD, Turner AR, 
  Wadleigh M, Sirulnik A, Galinsky I, Sallan SE, Stone RM. A multicenter phase II study 
  using a dose intensified pediatric regimen in adults with untreated acute lymphoblastic 

- Dos Santos N, Chapman J, Andrews H, Meng D, Shepherd L, Pollak M, Li D, Wilson C, 
  Dunn S. Urokinase plasminogen activator is a serum marker for breast cancer 
  recurrence: a nested case-control pilot study by the NCIC Clinical Trials Group. Breast 
  Cancer Research and Treatment 100[Suppl 1], 2006.

- Eisenhauer E. Rational drug development in oncology: setting the scene for use of 

- El-Maraghi RH, Ellard S, Gelmon K, McIntosh L, Seymour L. Pulmonary changes in a 
  randomized phase II study of the mTOR inhibitor RAD001C (Everolimus): NCIC CTG 

- Florescu M, Hasan B, Shepherd FA, Seymour L, Ding K, Pater J. Identifying patients 
  with non-small cell lung cancer unlikely to benefit from erlotinib: An exploratory analysis 
  of National Cancer of Institute of Canada Clinical Trials Group BR.21. 

- Fuchs C, Tepper JE, Niedzwiecki D, Hollis D, Haller DG, Dragovich T, Alberts SR, 
  Bjarnason G, Mayer RJ. Postoperative adjuvant chemoradiation for gastric or 
  gastroesophageal adenocarcinoma using epirubicin, cisplatin, and infusional 5-FU 
  before and after CI 5-FU and radiotherapy: Interim toxicity results from Intergroup trial 

- Gauthier I, Laurie SA, Arnold A, Goss G, Ellis P, Chen E, Shepherd F, Matthews S, 
  Walsh W, Robertson J, Seymour L. Hypertension: Experience in IND.171, a phase I 
  dose-seeking trial combining AZD2171 with standard chemotherapy in patients with 
  advanced incurable non-small cell lung cancer. Presented: 8th International Symposium 
  on Anti-Agiogenic Agents, 2006.


O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Huntsman DG, Bramwell VH, Andrulis I, Pritchard KI. Topoisomerase II alpha protein overexpression has predictive utility in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5). Breast Cancer Research and Treatment 100[Suppl 1],S18, 2006.

O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Huntsman DG, Bramwell VH, Andrulis IL, Pritchard KI. Prognostic and predictive value of topoisomerase II alpha in a


- Thomas GM, Ali S, Patiel M, Abulafie O, Lucci JA, III. A GOG phase III trial to evaluate...
maintaining hemoglobin = 120 G/L with erythropoietin during chemoradiation for cervical cancer. Int J Gynecol Cancer 16[3], 603-604, 2006.


2005


- Goss PE, Ingle J, Tu D, Shepherd L, Pater J. NCIC CTG MA17: Disease free survival


Li D. Determinants of sample size and power in equivalence trials that compare binomial outcomes. Clinical Trials 2[Suppl 1], S59, 2005.

Li D. Can more frequent regular group sequential tests help to make an earlier conclusion in clinical trials? A retrospective evaluation. Clinical Trials 2[Suppl 1], 2005.


Messerschmidt T, Koski B. Integrating SOPs into a comprehensive website document management system. Clinical Trials 2[Suppl 1], S50, 2005.


2005.

- Tu D. Nonparametric estimate and confidence intervals for the hazard ratio based on censored data. Clinical Trials 2[Suppl 1], S36, 2005.

2004


Ding K. Point estimate following group sequential tests. ENAR Int Biometric Soc, 2004.


Gorlia T, Stupp R, Eisenhauer EA, Mirimanoff RO, van den Bent MJ, Belanger K, Lacombe D, Allgeier A. Clinical prognostic factors affecting survival in patients with...


Ehrenberger H, Bacon M, Burkes K, Lillington L, Ward K, Zimmerman J. The
development of a virtual work group of the ONS Clinical Trials Nurses Special Interest Group: Keys to productivity. Oncology Nursing Society, 2003.


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


2002


• Bezjak A, Perrone F, Gallo C, Hirsh V, Seymour L, Plantedosi F, Shepherd F, Robbiati


Madarnas Y, Fine S, Sawka C, Shepherd L, Tannock I, Tu D, Levine M. Body size,


• Crump M, Tu D, Shepherd L, Levine E, Bramwell V, Pritchard K. Risk of acute leukemia
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

following adjuvant epirubicin-based adjuvant chemotherapy for breast cancer. San

- Crump M, Gluck S, Stewart D, Levine M, Pritchard K, Kirkbride P, Dancey J, O'Reilly S,
  Shore T, Couban S, Giroud C, Abu-Zahra H, Tu D, Marlin S, Shepherd L. A randomized
trial of high-dose chemotherapy with autologous peripheral blood stem cell
support compared to standard therapy in women with metastatic breast cancer: a NCIC

  D, Jolivet J, McIntosh L, Seymour L. NCIC CTG IND 120: phase II study of
Troxacitabine (BCH-4556) in patients with advanced non-small cell lung cancer.

  Wright J, Blood P, Grafton C. NCIC CTG phase III trial of single versus 5 fraction
radiotherapy in the palliation of non-small cell lung cancer. Canadian Association

- Donehower RC, Stewart D, Eisenhauer E, Wainman N, Moore M, Bonfils C, Reid G. A
  phase I and pharmacokinetic study of MG98, a human DNA methyltransferase mRNA
inhibitor, given as a 2-hour weekly infusion 3 out of every 4 weeks. Clinical Cancer
Research 7(Suppl), 3680s, 2001.

- Douillard J, Petersen V, Shepherd F, Paz-Ares L, Arnold A, Tonato M, Ottaway J, Davis
  M, Van Vreckem A, Humphrey J, Seymour L. Randomised phase II study of
BMS-275291 versus placebo in patients with stage IIIb or IV non small cell lung cancer
37(suppl 6), S19, 2001.

- Eisenhauer E, Verweij J, Rothenberg M, Demetri G, de Vries E, Gelmon K, Hirte H, Loos
  W, Seiden M, Sparreboom A, Cameron T, Hamilton M, Ptaszynski M, Onetto N. Phase I
evaluation of liposomal topoisomerase I inhibitor, NX211, administered by three
schedules to patients with advanced solid tumors. Proc.Am.Soc.Clin.Oncol. 20, 103a,

- Gelmon K, Belanger K, Britten C, Soulieres D, Janke S, Dionne J, Powers J, Seymour L,
  McNally J. A phase I study of T900607 given once every three weeks to patients with
advanced refractory cancer. A NCIC Clinical Trials Group Study (NCIC CTG-IND.130).

- Gelmon K, Rothenberg M, Verweij J, Hirte H, Demetri G, Sparreboom A, Eisenhauer E,
de Vries E, Warren S, Hamilton M, Ptaszynski M, Onetto N. NX 211, a liposomal
camptothecin: phase I and pharmacokinetic results. Cancer Investigation 19(Suppl 1),

- Gelmon K, Stewart D, Ayers D, Fry D, Douglas L, McIntosh L, Seymour L. A phase I
study of ZD0473 and docetaxel given once every three weeks in patients with advanced
37(Suppl 6), S72, 2001.

- Gluck S, Crump M, Stewart D, Levine M, Pritchard K, Kirkbride P, Dancey J, O'Reilly S,
  Shore T, Couban S, Giroud C, Abu-Zahra H, Tu D, Marlin S, Shepherd L. A randomized
trial of high-dose chemotherapy with autologous peripheral blood stem cell support
compared to standard chemotherapy in women with metastatic breast cancer: a NCIC

IND.122: a phase I/II pharmacokinetics and pharmacodynamic study of ZD1839
(Iressa'TM'). Final phase I results and preliminary phase II results of ZD1839 (750


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


2000


21(2S), 114s, 2000.


1999


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

1998


Pater J, Bezjak A, Osoba D, Zee B, Palmer M. Quality of life as an endpoint in NCIC


1997


Dent S, Klaassen D, Pater J, Zee B, Whitehead M. Update of second primary malignancies and treatment results in women with early stage ovarian cancer.


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


1996


• Hall R. for MRC Advanced Bladder Cancer Working Party, EORTC GU Group, NCI Canada, Norwegian Bladder Cancer Group, Australian Bladder Cancer Study Group, Club Urologica Espanol de Tratamiento and FinBladder. Neo-adjuvant CMV chemotherapy and cystectomy or radiotherapy in muscle invasive bladder cancer. First


daunorubicin and cytosine arabinoside as induction therapy and all-trans retinoic acid versus observation as maintenance therapy for patients with previously untreated acute promyelocytic leukemia. Blood (ASH Annual Meeting Abstracts) 86[10 Suppl 1], 1996.

- Zee B. Phase II design for cancer clinical trials using multivariate endpoints. Biometric Society ENAR, 1996.

1995

- Latreille J, Johnston D, Laberge F, Stewart D, Rusthoven J, Nishimura L, Pater J, Zee B.
Use of granisetron and dexamethasone on day 2-7 following high dose cisplatin. Supportive Care in Cancer 3(5), 339, 1995.


- Lofters C, Zee B. Adding 5 HT3 antagonists to dexamethasone after 24 hours has a minimal effect in preventing delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Eur.J.Can. 31A(suppl.5), 255, 1995.


- Lofters W, Zee B. Adding 5HT3 antagonists to dexamethasone after twenty four hours has a minimal effect in preventing delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Supportive Care in Cancer 3(5), 339, 1995.


- Pater J, Zee B, Lofters W, Osoba D, Warr D, Palmer M, Chin C, Dempsey E. Effective


1994


- Eisenhauer E, Bacon M, Atri M, Lemort M, Nolan R, Petroons P, Sauerbrei E, Florczyk


- Zee B, James K, Johnston D. Design and analysis of late randomization trials:
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

1993


Tumour Research and Therapy, 1993.

- Paul N. The success of clinical trials depends on good communication. Joint meeting of EORTC SGDM and BODMA, 1993.
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Pater J, Niezgoda H, Zee B. Validation of the EORTC-QLC -- a comparison with four other instruments in a heterogenous group of cancer patients. Ann.Oncol. 3(Suppl.5), 175, 1992.
- Zee B. One-sided test for clinical trials with group sequential design that allow early
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


1991


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

1989


Palmer M, Pater J. Comparison of errors in body surface area and initial doses in five clinical trials (C0.2, C0.3, HD.4, MA.4, OV.8). Controlled Clin.Trials 10(3), 351, 1989.


1987

1986

- Wallenstein S, Patel HI, Willan A. Use of baseline values in the two period two treatment crossover design. Biometric Society ENAR, 1986.

1985
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


1984


1983


1981